Association Between Immune Checkpoint Inhibitors and the Hazard of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer Included in the French Real-Life ESME Cohort.
Researchers
Elisabeth Gaye, Clémence Leguillette, Léa Sinoquet, Marie-Cécile Le Deley, Stéphane Pouderoux, Frédéric Bigot, Victoria Ferrari, Nicolas Girard, Christos Chouaid, Didier Debieuvre, Yannick Le Guen, Jordi Remon-Masip, Grégoire Justeau, Clarisse Audigier Valette, Sophie Schneider, Olivier Bylicki, Thomas Filleron, Anne Madroszyk, Charles Dayen, Lionel Falchero, Pascale Dubray-Longeras, Courèche Kaderbhaï, Chrystèle Locher, Maurice Pérol, Anne-Laure Martin, Xavier Quantin, David Pasquier
Abstract
Immune checkpoint inhibitors (ICI) have dramatically changed the outcome of patients with non-small cell lung cancer (NSCLC) across all stages of the disease. Herein, we investigated the association between ICI as part of the first treatment (ICI-1) and the risk of onset of central nervous system (CNS) metastases (brain or leptomeningeal disease) in patients with advanced NSCLC (aNSCLC). We conducted a retrospective analysis of the real-world French Epidemiological Strategy and Medical Economics (ESME) cohort. We included all patients aged ≥ 18 years with aNSCLC and without CNS metastases at diagnosis, who started systemic treatment and/or radiotherapy between 2015 and 2020. We estimated the incidence of CNS metastases considering death and second cancer as competing events. We used cause-specific Cox models to evaluate the factors associated with the cause-specific hazard of CNS metastases, particularly the association between ICI-1 and the hazard of CNS metastases. Among 10,618 patients, 68.6% were male and 31.4% were female, 12.2% received ICI-1, with proportion increasing over time (4.3%  < 2017 versus 19.4% ≥ 2017, p < 0.001). Overall, the 5-year cumulative incidence of CNS metastases was 22.4% (95% CI 21.5-23.4%). In multivariable analysis, patients who received ICI-1 had a significantly lower cause-specific hazard of CNS metastases (cause-specific hazard ratio 0.60, 95% CI 0.51-0.71, p < 0.001), with stable results with the propensity score approach. A higher age, squamous NSCLC, and BRAF mutation were significantly associated with a reduced cause-specific hazard of CNS metastases. Conversely, the presence of non-CNS metastases and EGFR, KRAS, or STK11 mutations were significantly associated with a higher hazard of CNS metastases. On the basis of this real-world retrospective study, patients with aNSCLC appear to have a lower hazard of CNS metastases when treated with ICI-1.Source: PubMed (PMID: 43050112)View Original on PubMed